Concepts (174)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Israel | 16 | 2021 | 2751 | 1.01 | Why? |
| Influenza B virus | 4 | 2019 | 815 | 0.69 | Why? |
| Keratoconjunctivitis | 1 | 2017 | 41 | 0.65 | Why? |
| Influenza Vaccines | 5 | 2019 | 2941 | 0.61 | Why? |
| Adenoviridae Infections | 1 | 2017 | 150 | 0.61 | Why? |
| Influenza A Virus, H3N2 Subtype | 2 | 2018 | 572 | 0.61 | Why? |
| Influenza, Human | 8 | 2019 | 10779 | 0.58 | Why? |
| Natural Cytotoxicity Triggering Receptor 1 | 3 | 2017 | 21 | 0.54 | Why? |
| Influenza A Virus, H1N1 Subtype | 3 | 2018 | 2984 | 0.53 | Why? |
| Antigens, Ly | 3 | 2017 | 17 | 0.53 | Why? |
| Povidone-Iodine | 1 | 2017 | 213 | 0.53 | Why? |
| Seasons | 6 | 2019 | 4071 | 0.49 | Why? |
| Coronavirus 229E, Human | 1 | 2021 | 1241 | 0.48 | Why? |
| Ultraviolet Rays | 1 | 2020 | 1272 | 0.43 | Why? |
| Eye Infections, Viral | 1 | 2017 | 517 | 0.39 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.34 | Why? |
| Genetic Variation | 1 | 2021 | 3919 | 0.32 | Why? |
| Vaccine Potency | 2 | 2018 | 339 | 0.32 | Why? |
| High-Throughput Nucleotide Sequencing | 4 | 2021 | 3633 | 0.30 | Why? |
| Dexamethasone | 1 | 2017 | 2055 | 0.30 | Why? |
| Killer Cells, Natural | 3 | 2017 | 2093 | 0.25 | Why? |
| Genome, Viral | 3 | 2021 | 13157 | 0.24 | Why? |
| Spheroids, Cellular | 1 | 2021 | 124 | 0.22 | Why? |
| Phylogeny | 5 | 2020 | 13341 | 0.20 | Why? |
| Antibodies, Neutralizing | 3 | 2021 | 25288 | 0.20 | Why? |
| Parainfluenza Virus 3, Human | 1 | 2018 | 67 | 0.19 | Why? |
| Mammalian orthoreovirus 3 | 1 | 2017 | 2 | 0.18 | Why? |
| Influenza A virus | 3 | 2019 | 2234 | 0.18 | Why? |
| Oncolytic Viruses | 1 | 2017 | 20 | 0.18 | Why? |
| Respirovirus Infections | 1 | 2018 | 90 | 0.17 | Why? |
| Oncolytic Virotherapy | 1 | 2017 | 36 | 0.17 | Why? |
| Genetic Drift | 1 | 2017 | 54 | 0.17 | Why? |
| Paramyxoviridae Infections | 2 | 2018 | 364 | 0.17 | Why? |
| Vaccination | 6 | 2021 | 19050 | 0.17 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.16 | Why? |
| Mouthwashes | 1 | 2021 | 432 | 0.16 | Why? |
| Ophthalmic Solutions | 1 | 2017 | 136 | 0.16 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.15 | Why? |
| Radiation Dosage | 1 | 2020 | 585 | 0.15 | Why? |
| Infant | 8 | 2019 | 30274 | 0.15 | Why? |
| Amino Acid Sequence | 2 | 2017 | 6049 | 0.15 | Why? |
| Chi-Square Distribution | 1 | 2018 | 961 | 0.15 | Why? |
| Madin Darby Canine Kidney Cells | 1 | 2017 | 640 | 0.14 | Why? |
| Respiratory Syncytial Viruses | 1 | 2018 | 612 | 0.14 | Why? |
| Metapneumovirus | 1 | 2017 | 465 | 0.13 | Why? |
| Air Travel | 1 | 2020 | 585 | 0.13 | Why? |
| Child, Preschool | 7 | 2019 | 36283 | 0.13 | Why? |
| Sentinel Surveillance | 2 | 2018 | 1093 | 0.13 | Why? |
| Travel-Related Illness | 1 | 2020 | 1357 | 0.12 | Why? |
| Hemagglutinin Glycoproteins, Influenza Virus | 1 | 2017 | 511 | 0.12 | Why? |
| Safety | 1 | 2021 | 1583 | 0.12 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.12 | Why? |
| Mutation | 3 | 2021 | 12376 | 0.12 | Why? |
| Humans | 31 | 2021 | 930598 | 0.11 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.11 | Why? |
| Asymptomatic Diseases | 2 | 2021 | 3444 | 0.11 | Why? |
| Virus Inactivation | 1 | 2020 | 1139 | 0.11 | Why? |
| Protein Domains | 2 | 2021 | 6563 | 0.11 | Why? |
| Adenoviridae | 1 | 2017 | 1151 | 0.11 | Why? |
| Health Personnel | 4 | 2021 | 29646 | 0.11 | Why? |
| Neutralization Tests | 2 | 2021 | 6698 | 0.10 | Why? |
| Heart Transplantation | 1 | 2021 | 1293 | 0.10 | Why? |
| Anti-Infective Agents, Local | 1 | 2017 | 520 | 0.10 | Why? |
| Whole Genome Sequencing | 1 | 2021 | 3239 | 0.10 | Why? |
| Adolescent | 10 | 2021 | 86841 | 0.10 | Why? |
| Amino Acid Substitution | 1 | 2017 | 1706 | 0.10 | Why? |
| Dogs | 1 | 2017 | 2529 | 0.10 | Why? |
| Child | 8 | 2019 | 70012 | 0.10 | Why? |
| Coronavirus | 1 | 2018 | 18339 | 0.09 | Why? |
| Middle Aged | 16 | 2021 | 270681 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2021 | 253789 | 0.09 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.09 | Why? |
| Adult | 14 | 2021 | 244371 | 0.09 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.08 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.08 | Why? |
| Models, Molecular | 2 | 2021 | 7616 | 0.08 | Why? |
| Female | 17 | 2021 | 380317 | 0.08 | Why? |
| Aged | 13 | 2021 | 215776 | 0.08 | Why? |
| DNA, Viral | 1 | 2017 | 2521 | 0.08 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 13720 | 0.08 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.08 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.08 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.07 | Why? |
| Hospitalization | 1 | 2017 | 54280 | 0.07 | Why? |
| Young Adult | 8 | 2021 | 93724 | 0.07 | Why? |
| Antibodies, Monoclonal | 2 | 2021 | 8041 | 0.07 | Why? |
| Cell Line | 1 | 2021 | 12040 | 0.07 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.07 | Why? |
| Male | 16 | 2021 | 367725 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 11367 | 0.07 | Why? |
| Europe | 1 | 2021 | 12702 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.06 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.06 | Why? |
| Mice | 5 | 2021 | 21357 | 0.06 | Why? |
| Patient Admission | 1 | 2019 | 5250 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2021 | 17020 | 0.06 | Why? |
| Mice, Transgenic | 2 | 2021 | 2739 | 0.06 | Why? |
| Postoperative Complications | 1 | 2021 | 5861 | 0.06 | Why? |
| Mice, Knockout | 2 | 2017 | 1815 | 0.06 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.06 | Why? |
| Mice, Inbred NOD | 1 | 2021 | 134 | 0.06 | Why? |
| Buffers | 1 | 2021 | 82 | 0.06 | Why? |
| Mice, SCID | 1 | 2021 | 225 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Glucocorticoids | 1 | 2017 | 4431 | 0.05 | Why? |
| Nasopharynx | 2 | 2018 | 10224 | 0.05 | Why? |
| Acute Kidney Injury | 1 | 2021 | 5762 | 0.05 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Aged, 80 and over | 6 | 2021 | 88759 | 0.05 | Why? |
| Animals | 6 | 2021 | 78931 | 0.05 | Why? |
| Infant, Newborn | 2 | 2018 | 23105 | 0.05 | Why? |
| Cytopathogenic Effect, Viral | 1 | 2021 | 635 | 0.05 | Why? |
| Viral Proteins | 1 | 2017 | 7370 | 0.05 | Why? |
| Masks | 1 | 2020 | 8528 | 0.04 | Why? |
| Melanoma, Experimental | 1 | 2017 | 57 | 0.04 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.04 | Why? |
| Respiratory Tract Infections | 1 | 2018 | 6817 | 0.04 | Why? |
| Lymphocyte Activation | 2 | 2017 | 2742 | 0.04 | Why? |
| Immunoglobulin G | 1 | 2020 | 21571 | 0.04 | Why? |
| Mice, Inbred BALB C | 2 | 2017 | 5814 | 0.04 | Why? |
| Antibody Affinity | 1 | 2021 | 1078 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.04 | Why? |
| N-Acetylneuraminic Acid | 1 | 2017 | 198 | 0.04 | Why? |
| Critical Care | 1 | 2019 | 14081 | 0.04 | Why? |
| Cytotoxicity, Immunologic | 1 | 2017 | 287 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Treatment Outcome | 2 | 2021 | 51732 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.03 | Why? |
| Vero Cells | 2 | 2021 | 14117 | 0.03 | Why? |
| Ships | 1 | 2020 | 1046 | 0.03 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.03 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2018 | 43792 | 0.03 | Why? |
| Cells, Cultured | 1 | 2021 | 5835 | 0.02 | Why? |
| Primary Health Care | 2 | 2018 | 4839 | 0.02 | Why? |
| Disease Models, Animal | 2 | 2017 | 10998 | 0.02 | Why? |
| Epitopes | 1 | 2021 | 4113 | 0.02 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2020 | 3567 | 0.02 | Why? |
| Epithelial Cells | 1 | 2021 | 3508 | 0.02 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2018 | 1234 | 0.02 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.02 | Why? |
| Lung | 1 | 2017 | 31049 | 0.02 | Why? |
| Interferon Type I | 1 | 2021 | 2789 | 0.02 | Why? |
| Antibody Formation | 1 | 2021 | 4038 | 0.02 | Why? |
| Cohort Studies | 2 | 2021 | 36005 | 0.02 | Why? |
| Kidney | 1 | 2021 | 3648 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Melanoma | 1 | 2017 | 1229 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Binding Sites | 1 | 2017 | 6201 | 0.02 | Why? |
| Receptors, Virus | 1 | 2021 | 5659 | 0.02 | Why? |
| Antigens, Viral | 1 | 2021 | 6298 | 0.02 | Why? |
| Models, Biological | 1 | 2021 | 4907 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2020 | 9091 | 0.02 | Why? |
| Spike Glycoprotein, Coronavirus | 2 | 2021 | 37182 | 0.01 | Why? |
| Virus Replication | 1 | 2021 | 14331 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.01 | Why? |
| Time Factors | 1 | 2021 | 31397 | 0.01 | Why? |
| Comorbidity | 1 | 2019 | 34796 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
Mandelboim's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(174)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(236)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_